Bayer: Renal Insufficiency trials
The registry lists 12 Renal Insufficiency studies with Bayer as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 8Phase 4 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of Copanlisib in Hepatic or Renal ImpairmentCompletedNCT03172884Phase 1Results posted
- Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal ImpairmentCompletedNCT01853046Phase 1Results posted
- Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of MagnevistCompletedNCT00744939Results posted
- A Methodological Study to Learn More About Kidney Function in Healthy People and in People With Reduced Kidney FunctionCompletedNCT07368712Not applicable
- A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney FunctionCompletedNCT05599997Phase 1
- A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and WeightCompletedNCT05515432Phase 1
- A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney FunctionWithdrawnNCT05406219Phase 1
- Study to Assess the Safety, Tolerability, Effects on the Body, Absorption, Distribution and Elimination of 25 mg BAY2433334 in Renal Impairment Including Renal Replacement Therapy ("Dialysis")CompletedNCT04510987Phase 1
- Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal DysfunctionCompletedNCT03359876
- Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy SubjectsCompletedNCT03235076Phase 1
- Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)CompletedNCT02894385Phase 1
- Safety of Gadovist in Renally Impaired PatientsCompletedNCT00828737Phase 4